Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan M Webb

Showing results (141-150 of 178) with videos related to

Pageof 18
Sort By:
European Journal of Endocrinology|May 24, 2018
A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegalyPeter J Trainer, John D C Newell-Price, John Ayuk, et al.
European Journal of Endocrinology|December 26, 2023
High prevalence of venous thrombotic events in Cushing's syndrome: data from ERCUSYN and details in relation to surgeryKristina Isand, Richard Feelders, Thierry Brue, et al.
The Journal of Clinical Endocrinology and Metabolism|March 23, 2006
Ghrelin is produced by and directly activates corticotrope cells from adrenocorticotropin-secreting adenomasAntonio J Martínez-Fuentes, Jesús Moreno-Fernández, Rafael Vázquez-Martínez, et al.
Clinical Endocrinology|March 12, 2014
Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish studyGemma Sesmilo, Eugenia Resmini, Ignacio Bernabeu, et al.
Clinical Genetics|January 21, 2022
CIBERER: Spanish national network for research on rare diseases: A highly productive collaborative initiativeJuan Luque, Ingrid Mendes, Beatriz Gómez, et al.
The Journal of Clinical Endocrinology and Metabolism|January 16, 2014
Growth hormone should be used only for approved indicationsDavid R Clemmons, Mark Molitch, Andrew R Hoffman, et al.
European Journal of Endocrinology|October 13, 2004
Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA)Antonio Mestron, Susan M Webb, Ricardo Astorga, et al.
European Journal of Endocrinology|July 1, 2011
The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristicsElena Valassi, Alicia Santos, Maria Yaneva, et al.
Endocrine|January 12, 2024
Clinical and outcome comparison of genetically positive vs. negative patients in a large cohort of suspected familial hypocalciuric hypercalcemiaQueralt Asla, Helena Sardà, Núria Seguí, et al.
Clinical Endocrinology|March 26, 2018
Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the ERCUSYNElena Valassi, Richard Feelders, Dominique Maiter, et al.
Pageof 18

Showing results (141-150 of 178) with videos related to

Sort By:
Pageof 18
European Journal of Endocrinology|May 24, 2018
A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegalyPeter J Trainer, John D C Newell-Price, John Ayuk, et al.
European Journal of Endocrinology|December 26, 2023
High prevalence of venous thrombotic events in Cushing's syndrome: data from ERCUSYN and details in relation to surgeryKristina Isand, Richard Feelders, Thierry Brue, et al.
The Journal of Clinical Endocrinology and Metabolism|March 23, 2006
Ghrelin is produced by and directly activates corticotrope cells from adrenocorticotropin-secreting adenomasAntonio J Martínez-Fuentes, Jesús Moreno-Fernández, Rafael Vázquez-Martínez, et al.
Clinical Endocrinology|March 12, 2014
Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish studyGemma Sesmilo, Eugenia Resmini, Ignacio Bernabeu, et al.
Clinical Genetics|January 21, 2022
CIBERER: Spanish national network for research on rare diseases: A highly productive collaborative initiativeJuan Luque, Ingrid Mendes, Beatriz Gómez, et al.
The Journal of Clinical Endocrinology and Metabolism|January 16, 2014
Growth hormone should be used only for approved indicationsDavid R Clemmons, Mark Molitch, Andrew R Hoffman, et al.
European Journal of Endocrinology|October 13, 2004
Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA)Antonio Mestron, Susan M Webb, Ricardo Astorga, et al.
European Journal of Endocrinology|July 1, 2011
The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristicsElena Valassi, Alicia Santos, Maria Yaneva, et al.
Endocrine|January 12, 2024
Clinical and outcome comparison of genetically positive vs. negative patients in a large cohort of suspected familial hypocalciuric hypercalcemiaQueralt Asla, Helena Sardà, Núria Seguí, et al.
Clinical Endocrinology|March 26, 2018
Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the ERCUSYNElena Valassi, Richard Feelders, Dominique Maiter, et al.
Pageof 18